Core Business: Clinical-stage biotech developing the Bisphosphocin® class of fast-acting, broad-spectrum antimicrobials targeting antibiotic-resistant bacteria (e.g., MRSA, VRE) for applications including infected diabetic foot ulcers (lead candidate Nu-3 in Phase 2), skin, bladder, and pulmonary infections.
Headquarters: University Park, Florida (formerly referenced as Bradenton/Sarasota area).
Employees: Approximately 5 full-time.
Website: lakewoodamedex.com
Market Position: Micro-cap (market cap ~$4–5 million as of early July 2026 data).
Interpretation: The company positions its platform as a potential solution to the global antimicrobial resistance crisis, emphasizing speed and topical/local delivery to reduce hospital stays and resistance risks.
Founding and Early Years: Incorporated July 11, 2006, in Delaware as Nu Pharmas, Inc.; focused initially on antisense RNA research and oligonucleotide manufacturing. Acquired assets from Renaissance Nutraceuticals (2007) and Lakewood Pharmaceuticals (2007), leading to name change to Amedex Therapeutics, then Lakewood-Amedex Inc. (2008).
Recent Developments: Name changed to Lakewood-Amedex Biotherapeutics, Inc. in June 2025; redomiciled to Nevada; 1-for-5.92 reverse stock split in September 2025. Direct listing on Nasdaq Capital Market on April 23, 2026, under ticker LABT.
Uncertainties: Limited detailed public financial history or clinical trial outcomes available; as a small pre-revenue entity, much information derives from press releases and SEC filings.
| Year | Event (Facts) |
|---|---|
| 2006 | Incorporated as Nu Pharmas, Inc. |
| 2007–2008 | Asset acquisitions and name changes to Lakewood-Amedex Inc. |
| June 2025 | Renamed to Lakewood-Amedex Biotherapeutics, Inc. |
| Sept 2025 | Reverse stock split (1-for-5.92) |
| Apr 23, 2026 | Direct Nasdaq listing (LABT) |
Recent Price (as of ~July 8–10, 2026 data points): Trading around $2.30–$2.60 (highly variable intraday); significant daily swings common.
52-Week Range: Low ~$2.10 – High $98.20.
Market Cap: Approximately $4–5 million.
Volume: Average daily ~200k–450k shares; often elevated post-listing.
Financial Metrics: Negative EPS (~-$3.26 TTM); no revenue; net losses in millions.
Interpretation: Extreme volatility likely reflects low float, retail trading interest around the Nasdaq debut, and typical micro-cap biotech dynamics rather than fundamental changes.
| Metric | Value | Notes |
|---|---|---|
| Current Price | ~$2.30–2.60 | Fluctuating; e.g., one snapshot showed +9% move |
| 52W High | $98.20 | Post-listing peak |
| 52W Low | ~$2.10 | Recent lows |
| Market Cap | ~$4M | Micro-cap classification |
| YTD/1Y Return | Variable (one source noted +96% YTD but context of high volatility) | Short trading history post-listing |
Links for More Information:
Interpretation: News flow centers on clinical progress, IP strengthening, and policy advocacy, typical for advancing biotech assets.
Disclaimer: This is not financial advice. All information is for informational purposes only. Verify with primary sources as data is time-sensitive.